illimaquinone has been researched along with Colonic Neoplasms in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Choi, JH; Chung, YC; Do, MT; Hwang, IH; Jeong, HG; Jeong, TC; Jin, SW; Khanal, T; Kim, HG; Kim, HS; Na, M; Oh, SH | 1 |
Chung, KJ; Chung, YH; Gwak, J; Hwang, IH; Ju, BG; Kim, DE; Lee, HY; Na, M; Oh, S; Park, S; Song, GY; Yun, E | 1 |
2 other study(ies) available for illimaquinone and Colonic Neoplasms
Article | Year |
---|---|
Ilimaquinone induces death receptor expression and sensitizes human colon cancer cells to TRAIL-induced apoptosis through activation of ROS-ERK/p38 MAPK-CHOP signaling pathways.
Topics: Apoptosis; Base Sequence; Cell Line, Tumor; Colonic Neoplasms; DNA Primers; Enzyme Activation; Humans; Mitogen-Activated Protein Kinases; Proton Magnetic Resonance Spectroscopy; Quinones; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Receptors, Death Domain; Sesquiterpenes; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand; Transcription Factor CHOP; Up-Regulation | 2014 |
Activation of p53 with ilimaquinone and ethylsmenoquinone, marine sponge metabolites, induces apoptosis and autophagy in colon cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Benzoquinones; Cell Line, Tumor; Colonic Neoplasms; G2 Phase; HCT116 Cells; Humans; Quinones; Sesquiterpenes; Signal Transduction; Tumor Suppressor Protein p53 | 2015 |